Skip to search formSkip to main contentSkip to account menu

Pranlukast Hemihydrate

Known as: N-(4-Oxo-2-(1H-tetrazol-5-yl)-4H-1-benzopyran-8-yl)-p-(4-phenylbutoxy)benzamide Hemihydrate, SC-215745 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
A simple blending with α-glycosylated naringin produces enhanced solubility and absorption of pranlukast hemihydrate.
2015
2015
Improving dissolution and oral bioavailability of pranlukast hemihydrate by particle surface modification with surfactants and homogenization
The present study was carried out to develop an oral formulation of pranlukast hemihydrate with improved dissolution and oral… 
2013
2013
Self-microemulsifying drug-delivery system for improved oral bioavailability of pranlukast hemihydrate: preparation and evaluation
The purpose of the present investigation was to develop and evaluate a self-microemulsifying drug delivery system (SMEDDS) for… 
2011
2011
α-Glucosyl hesperidin induced an improvement in the bioavailability of pranlukast hemihydrate using high-pressure homogenization.
2007
2007
Preparation of drug nanoparticle-containing microparticles using a 4-fluid nozzle spray drier for oral, pulmonary, and injection dosage forms.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)